[
    {
        "header": "Generic threat to Valeant drug sends shares reeling",
        "time": "3:01PM UTC",
        "body": "TORONTO (Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO)(VRX.N) said new generic rivals cut into sales for one of its top drugs, overshadowing a sharp rise in quarterly earnings and sending its shares down 18 percent.\n\nSales of Wellbutrin XL, an antidepressant that accounted for about 7 percent of revenue in the second quarter, would likely keep falling, Valeant said.\n\nThe company, one of the most acquisitive in healthcare, sees difficulties ahead in the United States, one of its main markets.\n\n\u201cThere were no major red flags, just some yellow flags like the pace of the decline of Wellbutrin,\u201d said Susquehanna Financial analyst Gary Nachman, who termed the quarter as \u201cneither good, nor horrible\u201d. \u201cThe extent of the sell-off was a significant overreaction.\u201d\n\nThe stock had risen 78 percent since the start of the year, lifted by a string of acquisitions and Valeant\u2019s consistent record of topping estimates and raising its forecasts.\n\nThursday\u2019s decline wiped out nearly $2.8 billion of Valeant\u2019s $15.5 billion market capitalization.\n\n\u201cThe share price fall suggests something is fundamentally broken, but that\u2019s not the case,\u201d Canaccord Genuity analyst Neil Maruoka said. \u201cThe stock was priced to perfection.\u201d\n\nThe company reported its results on a day when stock markets around the world dived on concerns about the health of the global economy.\n\n\u201cInvestors were surprised by the level of competition they faced in neurology,\u201d Morningstar analyst David Krempa said. \u201cWellbutrin has already been losing market share and they\u2019ve just been trying to hold steady.\u201d\n\nValeant\u2019s second-quarter net earnings rose to $56 million, or 17 cents a share, from $34 million, or 21 cents, a year earlier. The per-share figure dropped as the number of shares outstanding doubled.\n\nCash earnings were 73 cents a share, including an extraordinary gain of 6 cents a share. Revenue was $609 million.\n\nCash earnings per share is arrived at using the cash flow instead of the net income.\n\nThe company sees third-quarter earnings of 55 cents to 60 cents a share, implying that Valeant will have a lot of work to do in the fourth quarter to meet 2011 targets, Nachman said.\n\nShares of Valeant dropped 15 percent at C$42.69 on the Toronto Stock Exchange and were down 16 percent at $43.77 on the New York Stock Exchange by Thursday mid-afternoon.\n\nValeant President Rajiv De Silva said on a conference call with analysts that U.S. Medicare reform held back second-quarter sales and the company would face more headwinds in the United States in the second half of the year.\n\nThe company still raised its earnings forecast for the year by 5 cents a share and said it expects to meet its annual revenue growth target of 8 percent, excluding new acquisitions.\n\nLast month, media reports said Valeant had approached Swedish specialty drug maker Meda AB MEDAa.ST about a possible acquisition.\n\nValeant dropped a $5.7 billion bid for U.S. drugmaker Cephalon Inc CEPH.O in May. Chief Executive Michael Pearson told Reuters last month it was seeking acquisition targets.",
        "link": "http://www.reuters.com/article/2011/08/04/us-valeant-idUSTRE7733E020110804"
    },
    {
        "header": "RPT-UPDATE 4-Generic threat to Valeant drug sends shares reeling",
        "time": "3:06PM UTC",
        "body": "* Shares fall 18 pct after 78 pct increase this year (Adds comments, details; In U.S. dollars unless noted. Corrects typo in 5th paragraph)\n\nTORONTO, Aug 4 (Reuters) - Valeant Pharmaceuticals International Inc (VRX.TO)(VRX.N) said new generic rivals cut into sales for one of its top drugs, overshadowing a sharp rise in quarterly earnings and sending its shares down 18 percent.\n\nSales of Wellbutrin XL, an antidepressant that accounted for about 7 percent of revenue in the second quarter, would likely keep falling, Valeant said.\n\nThe company, one of the most acquisitive in healthcare, sees difficulties ahead in the United States, one of its main markets.\n\n\u201cThere were no major red flags, just some yellow flags like the pace of the decline of Wellbutrin,\u201d said Susquehanna Financial analyst Gary Nachman, who termed the quarter as \u201cneither good, nor horrible\u201d. \u201cThe extent of the sell-off was a significant overreaction.\u201d\n\nThe stock had risen 78 percent since the start of the year, lifted by a string of acquisitions and Valeant\u2019s consistent record of topping estimates and raising its forecasts.\n\nThursday\u2019s decline wiped out nearly $2.8 billion of Valeant\u2019s $15.5 billion market capitalization.\n\n\u201cThe share price fall suggests something is fundamentally broken, but that\u2019s not the case,\u201d Canaccord Genuity analyst Neil Maruoka said. \u201cThe stock was priced to perfection.\u201d\n\nThe company reported its results on a day when stock markets around the world dived on concerns about the health of the global economy.\n\n\u201cInvestors were surprised by the level of competition they faced in neurology,\u201d Morningstar analyst David Krempa said. \u201cWellbutrin has already been losing market share and they\u2019ve just been trying to hold steady.\u201d\n\nValeant\u2019s second-quarter net earnings rose to $56 million, or 17 cents a share, from $34 million, or 21 cents, a year earlier. The per-share figure dropped as the number of shares outstanding doubled.\n\nCash earnings were 73 cents a share, including an extraordinary gain of 6 cents a share. Revenue was $609 million.\n\nCash earnings per share is arrived at using the cash flow instead of the net income.\n\nThe company sees third-quarter earnings of 55 cents to 60 cents a share, implying that Valeant will have a lot of work to do in the fourth quarter to meet 2011 targets, Nachman said.\n\nShares of Valeant dropped 15 percent at C$42.69 on the Toronto Stock Exchange and were down 16 percent at $43.77 on the New York Stock Exchange by Thursday mid-afternoon.\n\nValeant President Rajiv De Silva said on a conference call with analysts that U.S. Medicare reform held back second-quarter sales and the company would face more headwinds in the United States in the second half of the year.\n\nThe company still raised its earnings forecast for the year by 5 cents a share and said it expects to meet its annual revenue growth target of 8 percent, excluding new acquisitions.\n\nLast month, media reports said Valeant had approached Swedish specialty drug maker Meda AB MEDAa.ST about a possible acquisition.\n\nValeant dropped a $5.7 billion bid for U.S. drugmaker Cephalon Inc CEPH.O in May. Chief Executive Michael Pearson told Reuters last month it was seeking acquisition targets.",
        "link": "http://www.reuters.com/article/2011/08/04/valeant-idUSN1E77307620110804"
    }
]